{"id":391099,"date":"2016-07-25T00:00:00","date_gmt":"2016-07-25T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/emthon0003-2016-biopharma-non-hodgkins-lymphoma-and-chronic-lymphocytic-leukemia-emerging-therapies-venclexta-venetoclax\/"},"modified":"2026-04-14T10:28:06","modified_gmt":"2026-04-14T10:28:06","slug":"emthon0003-2016-biopharma-non-hodgkins-lymphoma-and-chronic-lymphocytic-leukemia-emerging-therapies-venclexta-venetoclax","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/emthon0003-2016-biopharma-non-hodgkins-lymphoma-and-chronic-lymphocytic-leukemia-emerging-therapies-venclexta-venetoclax\/","title":{"rendered":"Non-Hodgkin&#8217;s Lymphoma and Chronic Lymphocytic Leukemia | Emerging Therapies | Venclexta (venetoclax) | US | Wave 1 | 2016"},"content":{"rendered":"<p>LaunchTrends: Venclexta (Wave 1) is the first in a series of syndicated reports designed to track physician perception, uptake, and competitive environment regarding the newly launched chronic lymphocytic leukemia (CLL) drug Venclexta (Roche\/AbbVie\u2019s venetoclax). LaunchTrends: Venclexta measures the impact of this novel agent on the relapsed\/refractory CLL with del(17p) therapy market following launch, based on a blend of quantitative and qualitative primary research with U.S. hematologist-oncologists. The report evaluates physicians\u2019 current awareness and perception of Venclexta relative to other currently available therapies for relapsed\/refractory CLL, current and anticipated use of Venclexta, and promotional activity of Venclexta.<\/p>\n<p><strong>Questions Answered:<\/strong><\/p>\n<ul>\n<li>What are the awareness of and familiarity with Venclexta among hematologist-oncologists?<\/li>\n<li>What are the perceived clinical advantages and disadvantages of Venclexta compared with other marketed agents used for treating relapsed\/refractory CLL?<\/li>\n<li>To what extent is Venclexta currently being used by surveyed hematologist-oncologists? Where does Venclexta fit in the treatment algorithm? What reasons do nonprescribers give for not having prescribed Venclexta?<\/li>\n<li>What promotional messages are being employed by Roche\/AbbVie?<\/li>\n<\/ul>\n<p><strong>Scope:<\/strong><\/p>\n<p><strong>Market covered: <\/strong>United States.<\/p>\n<p><strong>Primary research: <\/strong>74 hematologist-oncologists; qualitative interviews with 10 respondents.<\/p>\n<p><strong>Indication coverage: <\/strong>Relapsed\/refractory CLL.<\/p>\n","protected":false},"template":"","class_list":["post-391099","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-hodgkins-lymphoma","biopharma-therapy-areas-non-hodgkins-lymphoma-and-chronic-lymphocytic-leukemia","biopharma-product-emerging-therapies","biopharma-geography-us","biopharma-date-858"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391099","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391099\/revisions"}],"predecessor-version":[{"id":394222,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391099\/revisions\/394222"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=391099"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}